Cargando…

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †

The main protease (M(pro)) of the betacoronavirus SARS-CoV-2 is an attractive target for the development of treatments for COVID-19. Structure-based design is a successful approach to discovering new inhibitors of the M(pro). Starting from crystal structures of the M(pro) in complexes with the Hepat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Göhl, Matthias, Zhang, Linlin, El Kilani, Haifa, Sun, Xinyuanyuan, Zhang, Kaixuan, Brönstrup, Mark, Hilgenfeld, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268446/ https://www.ncbi.nlm.nih.gov/pubmed/35807537 http://dx.doi.org/10.3390/molecules27134292

Ejemplares similares

Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease
por: Cooper, Mark S., et al.
Publicado: (2022)

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
por: Zhang, Linlin, et al.
Publicado: (2020)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond
por: de Oliveira, Vinicius Martins, et al.
Publicado: (2022)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

An Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease
por: Clayton, Joseph, et al.
Publicado: (2023)

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
por: Alugubelli, Yugendar R., et al.
Publicado: (2022)

Boceprevir
Publicado: (2012)

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
por: BATIBAY, Gönül S., et al.
Publicado: (2023)

Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds
por: Zhang, Linlin, et al.
Publicado: (2021)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Identification of a Dual Inhibitor of Secreted Phospholipase A(2) (GIIA sPLA(2)) and SARS-CoV-2 Main Protease
por: Theodoropoulou, Maria A., et al.
Publicado: (2022)

Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: A virtual screening approach
por: Borkotoky, Subhomoi, et al.
Publicado: (2021)

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
por: Xia, Zilei, et al.
Publicado: (2021)

Boceprevir-induced Herpes Zoster
por: Babalı, Ayşegul, et al.
Publicado: (2018)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

A suitable drug structure for interaction with SARS‐CoV‐2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study
por: Yoosefian, Mehdi, et al.
Publicado: (2023)

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease
por: Zhu, Lili, et al.
Publicado: (2011)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity
por: Kneller, Daniel, et al.
Publicado: (2022)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Erratum to: Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode
por: Chen, Shuai, et al.
Publicado: (2010)

Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease
por: Lin, Yuxi, et al.
Publicado: (2021)

Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
por: Jain, Rashi, et al.
Publicado: (2020)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease
por: Li, Yan, et al.
Publicado: (2021)

Boceprevir and personalized medicine in hepatitis C virus infection
por: Habersetzer, François, et al.
Publicado: (2012)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Acute pancreatitis associated with boceprevir: a case report
por: Bilar, Juliana Miguel, et al.
Publicado: (2014)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
por: Yang, Haitao, et al.
Publicado: (2005)

Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease
por: Pinzi, Luca, et al.
Publicado: (2021)

Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease
por: Wan, Shunzhou, et al.
Publicado: (2021)

Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study
por: Refaey, Rana H., et al.
Publicado: (2021)

Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_82s21iu00n04lanan32n2dgel3